US link-up to develop tissue regeneration products:
This article was originally published in Clinica
Osiris Therapeutics and California-based Activated Cell Therapy have agreed to develop structural and connective tissue regeneration products. Osiris will have exclusive rights to use Activated Cell Therapy's cell isolation and enrichment technology for the recovery of mesenchymal stem cells. Osiris, based in Baltimore, Maryland, intends to use the stem cells to develop cell therapy products to treat diseased or damaged structural and connective tissues.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.